Sfoglia per AUTORE
GERDS AT
Collezione AOU Novara
Items : 2
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. in Nature medicine / Nat Med. 2025 May;31(5):1531-1538. doi: 10.1038/s41591-025-03572-3. Epub 2025 Mar 10.
2025
AOU Novara
AOU Novara
Rampal RK; Grosicki S; Chraniuk D; Abruzzese E; Bose P; Gerds AT; Vannucchi AM; Palandri F; Lee SE; Gupta V; Lucchesi A; Oh ST; Kuykendall AT; Patriarca A; Álvarez-Larrán A; Mesa R; Kiladjian JJ; Talpaz M; Scandura JM; Lavie D; Harris M; Kays SK; Li Q; Boxhammer R; Brown B; Jegg AM; Harrison CN; Mascarenhas J;
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. in Future oncology (London, England) / Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11.
2022
AOU Novara
AOU Novara
Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J;